Medication Review as a Tool for Preventing Drug-Related Harm

Abstract

Medication review is a critical, structured process designed to optimize pharmacotherapy and minimize adverse drug events, particularly in vulnerable populations such as the elderly and patients with complex comorbidities. Recent evidence demonstrates that systematic medication reviews, when implemented as part of multidisciplinary care, significantly reduce drug-related harm, hospitalizations, and healthcare costs. This article examines the epidemiology of drug-related harm, pathophysiological mechanisms underlying adverse drug reactions, key risk factors, and the clinical application of medication reviews. Emphasis is placed on recent guideline recommendations, practical implementation strategies, and emerging innovations in medication safety.

Introduction

Drug-related harm remains a major cause of morbidity and mortality in clinical practice, with polypharmacy and inappropriate prescribing contributing substantially to adverse drug reactions (ADRs). The World Health Organization highlights medication safety as a global priority, advocating for system-level interventions to reduce preventable harm. Medication review, defined as a systematic evaluation of a patient's medications with the aim of optimizing therapy, is increasingly recognized as a cornerstone of patient safety and personalized care in all healthcare settings. This review article provides an in-depth analysis of the role of medication review in preventing drug-related harm, supported by current research and clinical practice guidelines.

Epidemiology / Disease Burden

Adverse drug events (ADEs) account for a significant proportion of emergency hospital admissions, particularly among older adults. Estimates suggest that up to 10% of hospital admissions in this demographic are related to medication issues. Polypharmacy, defined variably as the use of five or more medications, affects more than 40% of individuals over the age of 65. In addition, approximately one in ten patients will experience a preventable ADE during their hospital stay. The economic burden is substantial, with medication errors in the United States alone estimated to cost over $20 billion annually. The increasing prevalence of multimorbidity and complex treatment regimens underscores the urgent need for effective medication management strategies.

Pathophysiology

The pathophysiology of drug-related harm is multifactorial, involving pharmacokinetic and pharmacodynamic alterations, drug-drug and drug-disease interactions, and individual patient vulnerabilities. Age-related changes in renal and hepatic function alter drug metabolism and clearance, increasing the risk of accumulation and toxicity. Polypharmacy raises the probability of pharmacological interactions, while genetic variations can affect medication response and predispose to adverse effects. Moreover, the presence of multiple comorbidities may mask or mimic symptoms of ADRs, complicating clinical assessment. Mechanistically, inappropriate prescribing whether through omission, duplication, or incorrect dosing remains a major contributor to medication-related morbidity.

Risk Factors

Several risk factors increase susceptibility to drug-related harm. These include advanced age, renal or hepatic impairment, polypharmacy, cognitive dysfunction, low health literacy, and transitions of care between healthcare settings. The use of high-risk medications such as anticoagulants, antipsychotics, and hypoglycemic agents further escalates the likelihood of ADEs. Recent hospitalization, poor communication between healthcare providers, and inadequate review of medication history are also recognized contributors. Identification of these risk factors is essential in targeting populations who would benefit most from systematic medication review interventions.

Clinical Features

Clinical manifestations of drug-related harm are highly variable, ranging from mild gastrointestinal disturbances to life-threatening arrhythmias, hemorrhage, or organ failure. In older adults, ADRs often present atypically, with delirium, falls, or functional decline being common presentations. Adverse effects may be mistaken for progression of underlying disease, leading to diagnostic confusion and therapeutic escalation a phenomenon termed the prescribing cascade. Timely recognition of clinical features attributable to medication is fundamental in preventing further harm and optimizing patient outcomes.

Diagnosis

Diagnosis of drug-related harm requires a high index of suspicion and a systematic approach. Clinical assessment should include a comprehensive medication history, including over-the-counter and herbal supplements. Causality assessment tools such as the Naranjo algorithm or the Liverpool ADR Causality Assessment Tool can aid in determining the likelihood that a particular event is drug-related. Laboratory evaluation may be necessary to detect organ dysfunction or drug levels, while careful review of recent medication changes, dosages, and administration schedules provides invaluable diagnostic clues.

Treatment & Management

The cornerstone of management is prompt identification and withdrawal or dose adjustment of the offending agent. Supportive care, monitoring for resolution of symptoms, and patient education are vital components. A multidisciplinary approach, involving pharmacists, physicians, and nursing staff, has been shown to significantly improve outcomes. Medication review should be integrated into routine practice, particularly during transitions of care, to prevent recurrence. Documentation and communication of ADRs are essential for ongoing patient safety and quality improvement.

Recent Advances / Emerging Therapies

Technological innovations have enhanced the scope and efficacy of medication review processes. Clinical decision support systems (CDSS) integrated into electronic health records now offer automated alerts for potential drug interactions, dose errors, and contraindications. Pharmacogenomic testing is emerging as a promising tool for identifying patients at increased risk of ADRs based on their genetic makeup. New models of pharmacist-led medication review, including telepharmacy and virtual consultations, have expanded access and demonstrated effectiveness, particularly in remote or underserved communities. Ongoing research explores the use of artificial intelligence and machine learning to predict and prevent drug-related harm with greater precision.

Guideline Recommendations

International guidelines from organizations such as the National Institute for Health and Care Excellence (NICE), American Geriatrics Society (AGS), and WHO advocate for regular, structured medication review for all patients with polypharmacy or at high risk for ADEs. Key recommendations include the use of explicit criteria (e.g., Beers Criteria, STOPP/START) to identify potentially inappropriate medications, involvement of clinical pharmacists in multidisciplinary teams, and patient engagement in shared decision-making. Guidelines emphasize the importance of medication reconciliation during transitions of care and regular reassessment of therapy in light of evolving clinical status.

Conclusion

Medication review is an essential, evidence-based intervention for preventing drug-related harm in clinical practice. By systematically evaluating pharmacotherapy and addressing the multifactorial risks associated with polypharmacy and complex regimens, medication review optimizes patient safety, reduces healthcare utilization, and enhances quality of care. Ongoing advances in clinical decision support, pharmacogenomics, and integrated care models promise to further strengthen the impact of medication review. Commitment to guideline-informed, multidisciplinary implementation is paramount for achieving meaningful reductions in drug-related morbidity and mortality.